MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION

参与抗原加工的 MHC 基因

基本信息

  • 批准号:
    3147888
  • 负责人:
  • 金额:
    $ 6.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1992
  • 资助国家:
    美国
  • 起止时间:
    1992-01-01 至 1993-06-30
  • 项目状态:
    已结题

项目摘要

T lymphocyte activation, and hence the initiation of an immune response, requires recognition by T cell receptors of complexes consisting of peptide fragments of foreign antigens bound to major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC). Despite the critical nature of this first step in immune recognition, little is known about the mechanistic aspects of antigen processing, such as how the antigen fragments are produced, and how and where within the APC they encounter MHC molecules. A growing body of evidence suggests that the MHC contains genes which function in the transport of processed antigen into vesicles of the secretory system for binding by MHC class molecules and subsequent vesicular transport to the cell surface. The recent cloning of two MHC genes, called HAM1 and HAM2, which are homologous to a large superfamily of both prokaryotic and eukaryotic transporters represents a major step towards understanding the nature of antigen processing. This proposal deals with the structural and functional characterization of these two genes. Two types of experiments will be done to provide formal proof of the involvement of the HAM1 and HAM2 gene in antigen processing. First, full length, wild type HAM1 and HAM2 cDNAs will be introduced into cell lines carrying MHC-linked mutations that inactivate the antigen processing pathway. Second, mice deficient in HAM1 and HAM2 expression will be produced by introducing defective copies of these genes into embryonic stem cells by homologous recombination, and subsequently injecting these modified cells into mouse blastocysts. In order to further characterize the function of the HAM1 and HAM2 gene products, antibody will be produced to synthetic peptides derived from the deduced amino acid sequences. This antibody will be used immunohistochemically to localize the corresponding proteins within the cell (thus identifying the subcellular compartment where peptide meets MHC molecule), and to aid in their purification. Attempts will be made to reconstitute peptide transport in in vitro systems, and to analyze the specificity of the transport process. In addition to the above, the functional significance of two novel MHC class II-like genes will be addressed by examining their polymorphism and by producing antibody which would allow identification of the corresponding gene products.
T淋巴细胞激活,从而引发免疫反应,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John J. Monaco其他文献

Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes.
人类主要组织相容性复合体编码的抗原加工基因的基因组多态性、重组和连锁不平衡。
MHC class II region encoding proteins related to the muKidrug resistance family of transmembrane transporters
MHC Ⅱ类区域编码与跨膜转运蛋白 muKidrug 耐药家族相关的蛋白质
  • DOI:
    10.1038/348738a0
  • 发表时间:
    1990-12-27
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Edward V. Deverson;Irene R. Gow;W. John Coadwell;John J. Monaco;Geoffrey W. Butcher;Jonathan C. Howard
  • 通讯作者:
    Jonathan C. Howard
New class ll-like genes in the murine MHC
小鼠主要组织相容性复合体中的新型类 II 基因
  • DOI:
    10.1038/353573a0
  • 发表时间:
    1991-10-10
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Sungae Cho;Michelle Attaya;John J. Monaco
  • 通讯作者:
    John J. Monaco
Production of congenic Anti-Lyt-3.1 sera
  • DOI:
    10.1007/bf01844002
  • 发表时间:
    1978-12-01
  • 期刊:
  • 影响因子:
    2.900
  • 作者:
    Stephen C. Boos;John J. Monaco;Paul D. Gottlieb
  • 通讯作者:
    Paul D. Gottlieb

John J. Monaco的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John J. Monaco', 18)}}的其他基金

Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
  • 批准号:
    8701462
  • 财政年份:
    2014
  • 资助金额:
    $ 6.97万
  • 项目类别:
Proteasome subunit beta5t and thymus-specific peptides in T cell selection
T 细胞选择中的蛋白酶体亚基 beta5t 和胸腺特异性肽
  • 批准号:
    8824482
  • 财政年份:
    2014
  • 资助金额:
    $ 6.97万
  • 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
  • 批准号:
    2068671
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
  • 批准号:
    2068673
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
  • 批准号:
    2068672
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
  • 批准号:
    3148678
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
PROTEASOME-LMP COMPLEX AND ANTIGEN PROCESSING
蛋白酶体-LMP 复合物和抗原加工
  • 批准号:
    2003899
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
ROLE OF THE PROTEASOME/LMP COMPLEX IN ANTIGEN PROCESSING
蛋白酶体/LMP 复合物在抗原加工中的作用
  • 批准号:
    3148679
  • 财政年份:
    1993
  • 资助金额:
    $ 6.97万
  • 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
  • 批准号:
    3147889
  • 财政年份:
    1992
  • 资助金额:
    $ 6.97万
  • 项目类别:
MHC GENES INVOLVED IN ANTIGEN PROCESSING & PRESENTATION
参与抗原加工的 MHC 基因
  • 批准号:
    2067654
  • 财政年份:
    1992
  • 资助金额:
    $ 6.97万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 6.97万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 6.97万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 6.97万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 6.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 6.97万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 6.97万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 6.97万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 6.97万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 6.97万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 6.97万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了